- Report
- December 2022
- 44 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- December 2023
- 80 Pages
Vietnam
From €1365EUR$1,500USD£1,170GBP
- Report
- December 2023
- 80 Pages
Russia
From €1365EUR$1,500USD£1,170GBP
- Report
- December 2023
- 80 Pages
Japan
From €1365EUR$1,500USD£1,170GBP
- Report
- December 2023
- 80 Pages
Ireland
From €1365EUR$1,500USD£1,170GBP
- Report
- December 2023
- 80 Pages
Brazil
From €1365EUR$1,500USD£1,170GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- October 2022
- 210 Pages
Global
From €3249EUR$3,570USD£2,785GBP
Pyrimethamine is an antifolate drug used to treat a variety of infectious diseases, including toxoplasmosis, malaria, and isoniazid-resistant tuberculosis. It is also used to prevent and treat Pneumocystis jirovecii pneumonia in people with weakened immune systems. Pyrimethamine is available in both oral and injectable forms, and is often used in combination with other drugs.
The pyrimethamine market is driven by the increasing prevalence of infectious diseases, the growing demand for combination therapies, and the increasing availability of generic drugs. The market is also driven by the increasing number of clinical trials and the development of new formulations.
Companies in the pyrimethamine market include GlaxoSmithKline, Pfizer, Merck, Sanofi, Novartis, and Mylan. Show Less Read more